



January 31, 2019
Gene Techno Science Co., Ltd.
Code: 4584 (TSE Mothers)
Masaharu Tani, President & CEO

GTS and Senju sign a licensing agreement with Ocumension Therapeutics on biosimilar in ophthalmologic field

GTS and Senju have been working to develop biosimilars in ophthalmologic field in accordance with business collaboration agreement executed on May 12, 2016 and now concluded an exclusive licensing agreement with Ocumension Therapeutics (hereinafter, "Ocumension") on biosimilars in ophthalmologic field in China and Taiwan.

Ocumension is a china-based company which makes strategic alliances with global partners aiming at developing and providing drugs for, specifically, ophthalmologic diseases and has a new drug and technology portfolio in China. 6 Dimensions Capital, a leading healthcare investment firm in Chinese healthcare industry, has its 100% share of Ocumension. GTS, Senju and Ocumension will take respective role in accordance with this agreement for obtaining marketing authorization and commercialization of the drug in China and Taiwan. GTS and Senju will receive development milestone payments and as royalties based on sales revenue in the future.

Impact on the financial performance of GTS for the fiscal year ending March 2019 is being reviewed. If the revision of financial result will be necessary, such information shall be promptly disclosed.

Trade Name	Gene Techo Science Co., Ltd.
Representative	Masaharu Tani, President & CEO
Date of Incorporation	March 2001
Business lineup	Research and Development of biologics
Principal office	1, Kita-2, Nishi-9, Chuo-ku, Sapporo, 060-0002, Japan
Website	http://www.g-gts.com/
Trade Name	Senju Pharmaceutical Co., Ltd.
Representative	Yukoh Yoshida, President & CEO
Date of Incorporation	April 1947
Business line up	Pharmaceutical business: manufacture and sale of prescription eye, ear, nose and throat medicines, contact lens solutions and animal medicines
Principal office	Other business: manufacture and sale of raw materials for cosmetics 3-1-9, Kawara-machi, Chuo-ku, Osaka 541-0048, Japan
Website	http://www.senju.co.jp/
Trade Name	Ocumension Therapeutics
Representative	Ye Liu, CEO
Date of Incorporation	May 2018
Business lineup	Research and Development of Ophthalmological Product
Principal office	Room502-1, Want Want Plaza, No. 211 Shimen Yi Road, Jing'an District, Shanghai, PRC